Sana Biotechnology
Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.
Facts
- Sectors
- Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Yoodli launches AI platform to build courses, coach employees and track workplace skill gains after $300M+ valuation
Yoodli is expanding from AI practice sessions for public speaking into an “AI platform for human skills” that builds training courses, coaches employees during meetings, answers workplace questions, and tracks skill improvement. The startup—valued at over $300 million in December and backed with nearly $60 million from investors—aims to move into corporate training alongside firms like Workday and LinkedIn.
Sana Biotechnology Appoints Brian Piper as CFO; Aptevo CEO Marvin White to Step Down in April; Violett Names Scott Kushino CEO
Brian Piper was appointed CFO and executive vice president at Sana Biotechnology, while Marvin White will step down as Aptevo CEO in April, succeeded by COO Jeff Lamothe. Additionally, Scott Kushino became CEO of Seattle startup Violett, and several other leadership changes occurred across Seattle and New York tech companies.
Nobel Laureate David Baker Drives Protein Design Innovation and Startup Growth at University of Washington
David Baker, Nobel Prize winner and head of the Institute for Protein Design at the University of Washington, is focused on advancing protein design research and entrepreneurship, having helped spawn over 20 startups in Seattle's biotech hub. He plans to continue accelerating scientific innovation in the field, which develops new proteins for therapeutics, vaccines, and materials.
By Sana Biotechnology
See all 9Sana Biotechnology says SC451 Phase 1/2 and SG293 clinical studies nearing start; Q2 cash $160.5M, runway into mid-2027
Sana Biotechnology reported Q2 2026 progress toward initiating Phase 1/2 trial for SC451 in type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, highlighted by NEJM publication and upcoming EASD presentation for UP421 clinical data. The company presented SG293 and SG227 preclinical data, advanced a Mayo Clinic collaboration, and reported $160.5M cash with runway into mid-2027.
Sana Biotechnology develops engineered cells to repair genes and replace damaged or missing cells to treat disease
Sana Biotechnology develops engineered cells to repair or control genes and replace missing or damaged cells, aiming to address underlying causes of disease.
Sana Biotechnology Appoints Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA to Board of Directors
Sana Biotechnology appointed three new board members—Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA—to its Board of Directors. The additions expand Sana’s governance as it advances engineered cell therapies.
People
-
Steve Harr Co-founder and President and Chief Executive Officer
-
Snehal Patel Executive, Executive Vice President and Chief Technical Officer
Online
Questions about Sana Biotechnology
What is Sana Biotechnology?
Sana Biotechnology is a public company developing engineered cell and gene therapies to repair, control, or replace cells and address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders.
What has Sana Biotechnology been in the news for?
GeekWire reported in February 2026 that Sana Biotechnology appointed Brian Piper as CFO.
Who are the people behind Sana Biotechnology?
Steve Harr is co-founder, president and chief executive officer of Sana Biotechnology. Snehal Patel is executive vice president and chief technical officer.
Who invested in Sana Biotechnology, and how much has it raised?
Members of Seattle Flow see Sana Biotechnology's funding rounds, amounts and investors on its Funding tab. Joining is free.
When was Sana Biotechnology founded?
Sana Biotechnology was founded in 2018.